Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Validation of prognostic models of lung cancer

Principal Investigator
Name
Thomas Callender
Degrees
M.B.Ch.B., M.Sc.
Institution
University College London
Position Title
Wellcome Trust Clinical PhD Training Fellow
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-801
Initial CDAS Request Approval
Jun 21, 2021
Title
Validation of prognostic models of lung cancer
Summary
Lung cancer remains the foremost cause of death from cancer worldwide. Screening for lung cancer could lead to a ~20% reduction in lung-cancer–specific mortality. However, current eligibility criteria – age and cumulative smoking exposure – remain contested, and several studies have shown the potential benefits of risk-based eligibility for screening. The purpose of this project is to validate prognostic models of lung cancer that have been developed in the UK Biobank in order to determine eligibility for lung cancer screening.
Aims

1. To validate the predictive performance (calibration & discrimination) of prognostic models of lung cancer developed in the UK Biobank prior to implementation.

Collaborators

Professor Sam Janes, University College London

Related Publications